# Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease

> **NCT07212088** · PHASE1 · NOT_YET_RECRUITING · sponsor: **iCamuno Biotherapeutics Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **BIOLOGICAL:** ALC01 therapy

## Key facts

- **NCT ID:** NCT07212088
- **Lead sponsor:** iCamuno Biotherapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-28
- **Primary completion:** 2027-12-15
- **Final completion:** 2028-06-15
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07212088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07212088, "Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07212088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*